Cancer stem cell immunology: Key to understanding tumorigenesis and tumor immune escape?

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Bruttel, Valentin S ^a   Wischhusen, Jörg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cancer stem cell immunology; Cancer stem cells; Latency; Tumor dormancy; Tumor immune escape; Tumor immunology; Tumor immunosurveillance; Tumor propagating cells

Indexed keywords

EID: 84905639073     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00360     Document Type: Article

References (170)

1. Lodish HBA, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky SL, et al. Molecular Biology of the Cell. 5th ed. New York, NY: WH Freeman (2004).
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100(1):57-70. doi: 10.1016/S0092-8674(00)81683-9
3. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
4. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 9(8):568-80. doi:10.1038/nri2604
5. Haen SP, Rammensee HG. The repertoire of human tumor-associated epitopes - identification and selection of antigens and their application in clinical trials. Curr Opin Immunol (2013) 25(2):277-83. doi:10.1016/j.coi.2013.03.007
6. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2010) 463(7278):184-90. doi:10.1038/nature08629
7. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 465(7297):473-7. doi:10.1038/nature09004
8. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2010) 463(7278):191-6. doi:10.1038/nature08658
9. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 68(3):889-92. doi:10.1158/0008-5472.CAN-07-3095
10. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29:235-71. doi:10.1146/annurev-immunol-031210-101324
11. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6(10):715-27. doi:10.1038/nri1936
12. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-11. doi:10.1038/35074122
13. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 450(7171):903-7. doi:10.1038/nature06309
14. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 184(5):1781-90. doi:10.1084/jem.184.5.1781
15. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 192(5):755-60. doi:10.1084/jem.192.5.755
16. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 214(2):194-200. doi:10.1006/cimm.2001.1896
17. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 195(2):161-9. doi:10.1084/jem.20011171
18. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 168(3):1356-61. doi:10.4049/jimmunol.168.3.1356
19. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res (2003) 63(1):207-13.
20. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 118(1):111-23. doi:10.1172/JCI29900
21. Nepal RM, Zaheen A, Basit W, Li L, Berger SA, Martin A. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice. Oncogene (2008) 27(34):4752-6. doi:10.1038/onc.2008.111
22. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294(5542):605-9. doi:10.1126/science.1063916
23. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 28(4):571-80. doi:10.1016/j.immuni.2008.02.016
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
25. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg (2004) 30(4 Pt 2):622-7. doi:10.1097/00042728-200404020-00009
26. Tremblay F, Fernandes M, Habbab F, deB Edwardes MD, Loertscher R, Meterissian S. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol (2002) 9(8):785-8. doi:10.1007/BF02574501
27. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol (2005) 56(1):71-85. doi:10.1016/j.critrevonc.2004.11.010
28. Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology (2003) 185(3):229-40. doi:10.1016/S0300-483X(02)00612-1
29. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer (2001) 37(10):1188-201. doi:10.1016/S0959-8049(01)00120-4
30. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol (2000) 27(4):390-401.
31. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis (2006) 19(1):14-9. doi:10.1097/01.qco.0000200295.30285.13
32. de Magalhaes JP. How ageing processes influence cancer. Nat Rev Cancer (2013) 13(5):357-65. doi:10.1038/nrc3497
33. Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol (2010) 74(1):40-60. doi:10.1016/j.critrevonc.2009.06.002
34. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci (2010) 1197:158-65. doi:10.1111/j.1749-6632.2009.05370.x
35. Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing (2008) 5:11. doi:10.1186/1742-4933-5-11
36. Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, et al. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res (2012) 18(9):2526-33. doi:10.1158/1078-0432.CCR-12-0127
37. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 205(7):1687-700. doi:10.1084/jem.20072016
38. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med (2008) 205(13):2959-64. doi:10.1084/jem.20081611
39. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol (2010) 184(10):5637-44. doi:10.4049/jimmunol.0901644
40. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 482(7385):400-4. doi:10.1038/nature10755
41. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 482(7385):405-9. doi:10.1038/nature10803
42. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens (2008) 72(4):321-34. doi:10.1111/j.1399-0039.2008.01106.x
43. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21(2):137-48. doi:10.1016/j.immuni.2004.07.017
44. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 121(1):1-14. doi:10.1111/j.1365-2567.2007.02587.x
45. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 17(4):275-87. doi:10.1016/j.semcancer.2007.06.009
46. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, et al. Generation of a functional mammary gland from a single stem cell. Nature (2006) 439(7072):84-8. doi:10.1038/nature04372
47. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature (2006) 439(7079):993-7. doi:10.1038/nature04496
48. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 121(6):823-35. doi:10.1016/j.cell.2005.03.032
49. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A (2007) 104(1):181-6. doi:10.1073/pnas.0609684104
50. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 114(Pt 21):3865-72.
51. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci (2004) 117(Pt 16):3539-45. doi:10.1242/jcs.01222
52. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature (2007) 449(7165):1003-7. doi:10.1038/nature06196
53. Winton DJ, Ponder BA. Stem-cell organization in mouse small intestine. Proc Biol Sci (1990) 241(1300):13-8. doi:10.1098/rspb.1990.0059
54. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol (2009) 10(3):207-17. doi:10.1038/nrm2636
55. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature (2001) 414(6859):105-11. doi:10.1038/35102167
56. Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev Genet (2000) 1(1):57-64. doi:10.1038/35049577
57. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 202(11):1599-611. doi:10.1084/jem.20050967
58. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell (2000) 100(1):157-68. doi:10.1016/S0092-8674(00)81692-X
59. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell (2008) 135(6):1118-29. doi:10.1016/j.cell.2008.10.048
60. Nowell PC. The clonal evolution of tumor cell populations. Science (1976) 194(4260):23-8. doi:10.1126/science.959840
61. Ashley DJ. The two "hit" and multiple "hit" theories of carcinogenesis. Br J Cancer (1969) 23(2):313-28. doi:10.1038/bjc.1969.41
62. Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer (1953) 7(1):68-72. doi:10.1038/bjc.1953.8
63. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res (1964) 24:1544-51.
64. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 7(9):1028-34. doi:10.1038/nm0901-1028
65. Shlush LI, Chapal-Ilani N, Adar R, Pery N, Maruvka Y, Spiro A, et al. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and miscrosatellite instability. Blood (2012) 120(3):603-12. doi:10.1182/blood-2011-10-388629
66. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell (1991) 66(1):85-94. doi:10.1016/0092-8674(91)90141-K
67. Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface (2010) 7(Suppl 6):S753-63. doi:10.1098/rsif.2010.0353.focus
68. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 66(9):4553-7. doi:10.1158/0008-5472.CAN-05-3986
69. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 15(8):907-13. doi:10.1038/nm.2000
70. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 7(3):403-17. doi:10.1016/j.stem.2010.07.010
71. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science (2010) 329(5991):568-71. doi:10.1126/science.1189992
72. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 66(19):9339-44. doi:10.1158/0008-5472.CAN-06-3126
73. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126(4):663-76. doi:10.1016/j.cell.2006.07.024
74. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 108(19):7950-5. doi:10.1073/pnas.1102454108
75. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 69(7):2887-95. doi:10.1158/0008-5472.CAN-08-3343
76. Sharif A, Legendre P, Prevot V, Allet C, Romao L, Studler JM, et al. Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene (2007) 26(19):2695-706. doi:10.1038/sj.onc.1210071
77. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 146(4):633-44. doi:10.1016/j.cell.2011.07.026
78. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 490(7420):412-6. doi:10.1038/nature11538
79. Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, et al. VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation. Cancer Res (2014) 74(5):1566-75. doi:10.1158/0008-5472.CAN-13-1641
80. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 15(3):178-96. doi:10.1038/nrm3758
81. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science (2013) 342(6159):1234850. doi:10.1126/science.1234850
82. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 65(20):9328-37. doi:10.1158/0008-5472.CAN-05-1343
83. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 43(5):935-46. doi:10.1016/j.ejca.2007.01.017
84. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun (2008) 368(4):930-6. doi:10.1016/j.bbrc.2008.02.022
85. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 466(7302):133-7. doi:10.1038/nature09161
86. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med (2009) 15(9):1010-2. doi:10.1038/nm0909-1010
87. Eaves CJ. Cancer stem cells: here, there, everywhere? Nature (2008) 456(7222):581-2. doi:10.1038/456581a
88. Passegue E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nat Med (2009) 15(1):23. doi:10.1038/nm0109-23
89. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature (2008) 456(7222):593-8. doi:10.1038/nature07567
90. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 18(5):510-23. doi:10.1016/j.ccr.2010.10.012
91. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2(1):3. doi:10.1186/2001-1326-2-3
92. Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, et al. Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets (2014) 14(3):225-40. doi:10.2174/1568009614666140328152459
93. Hamai A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res (2008) 68(23):9854-64. doi:10.1158/0008-5472.CAN-08-0719
94. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 22(21):3205-12. doi:10.1038/sj.onc.1206394
95. Seliger B, Kiessling R. The two sides of HER2/neu: immune escape versus surveillance. Trends Mol Med (2013) 19(11):677-84. doi:10.1016/j.molmed.2013.08.003
96. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 191(12):6261-72. doi:10.4049/jimmunol.1301597
97. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 73(5):1635-46. doi:10.1158/0008-5472.CAN-12-3349
98. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1176:154-69. doi:10.1111/j.1749-6632.2009.04568.x
99. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 69(20):8058-66. doi:10.1158/0008-5472.CAN-09-0834
100. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 16(3):800-13. doi:10.1158/1078-0432.CCR-09-2730
101. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 21(1):39-55. doi:10.1111/j.1755-148X.2007.00427.x
102. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 11(3):259-73. doi:10.1016/j.ccr.2007.01.013
103. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res (2010) 70(5):2030-40. doi:10.1158/0008-5472.CAN-09-1707
104. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 1(4):389-402. doi:10.1016/j.stem.2007.08.001
105. Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res (2006) 66(1):571-80. doi:10.1158/0008-5472.CAN-05-1362
106. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun (2007) 364(4):778-82. doi:10.1016/j.bbrc.2007.10.067
107. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol (2008) 29(10):464-8. doi:10.1016/j.it.2008.07.005
108. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol (2007) 178(9):5595-605. doi:10.4049/jimmunol.178.9.5595
109. Maccalli C, Volonte A, Cimminiello C, Parmiani G. Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer (2014) 50(3):649-55. doi:10.1016/j.ejca.2013.11.014
110. Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 99(15):9864-9. doi:10.1073/pnas.142298299
111. Favier B, LeMaoult J, Carosella ED. Functions of HLA-G in the immune system. Tissue Antigens (2007) 69(Suppl 1):150-2. doi:10.1111/j.1399-0039.2006.763_6.x
112. Verloes A, Van de Velde H, LeMaoult J, Mateizel I, Cauffman G, Horn PA, et al. HLA-G expression in human embryonic stem cells and preimplantation embryos. J Immunol (2011) 186(4):2663-71. doi:10.4049/jimmunol.1001081
113. Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation (2007) 84(2):231-7. doi:10.1097/01.tp.0000267918.07906.08
114. Kroczek RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol (2004) 16(3):321-7. doi:10.1016/j.coi.2004.03.002
115. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2006) 24(2):386-98. doi:10.1634/stemcells.2005-0008
116. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy (2003) 5(6):485-9. doi:10.1080/14653240310003611
117. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 31(10):890-6. doi:10.1016/S0301-472X(03)00110-3
118. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2005) 105(4):1815-22. doi:10.1182/blood-2004-04-1559
119. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol (2002) 23(3):144-50. doi:10.1016/S1471-4906(01)02154-8
120. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 103(12):4619-21. doi:10.1182/blood-2003-11-3909
121. Bai L, Lennon DP, Caplan AI, Dechant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci (2012) 15(6):862-70. doi:10.1038/nn.3109
122. Benkhoucha M, Santiago-Raber ML, Schneiter G, Chofflon M, Funakoshi H, Nakamura T, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 107(14):6424-9. doi:10.1073/pnas.0912437107
123. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood (2003) 101(9):3722-9. doi:10.1182/blood-2002-07-2104
124. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant (2004) 33(6):597-604. doi:10.1038/sj.bmt.1704400
125. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation (2003) 75(3):389-97. doi:10.1097/01.TP.0000045055.63901.A9
126. McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med (1999) 5(12):1410-2. doi:10.1038/70986
127. Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet (2005) 366(9490):1005-12. doi:10.1016/S0140-6736(05)67380-1
128. Niemeyer P, Schonberger TS, Hahn J, Kasten P, Fellenberg J, Suedkamp N, et al. Xenogenic transplantation of human mesenchymal stem cells in a critical size defect of the sheep tibia for bone regeneration. Tissue Eng Part A (2010) 16(1):33-43. doi:10.1089/ten.TEA.2009.0190
129. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371(9624):1579-86. doi:10.1016/S0140-6736(08)60690-X
130. Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant (2012) 17(1):55-62. doi:10.1097/MOT.0b013e32834ee676
131. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 174(10):6477-89. doi:10.4049/jimmunol.174.10.6477
132. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 367(6464):645-8. doi:10.1038/367645a0
133. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 100(7):3983-8. doi:10.1073/pnas.0530291100
134. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (2004) 432(7015):396-401. doi:10.1038/nature03128
135. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science (2007) 317(5836):337. doi:10.1126/science.1142596
136. Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, et al. Characterization of stem cell-like cancer cells in immune-competent mice. Blood (2006) 108(12):3906-12. doi:10.1182/blood-2006-05-024687
137. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3(11):991-8. doi:10.1038/ni1102-991
138. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 7(11):834-46. doi:10.1038/nrc2256
139. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol (2005) 21:605-31. doi:10.1146/annurev.cellbio.21.012704.131525
140. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature (2014) 506(7488):328-33. doi:10.1038/nature13038
141. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-7. doi:10.1038/nature04186
142. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 32(3-4):449-64. doi:10.1007/s10555-013-9420-1
143. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, et al. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol (2007) 114(2):111-9. doi:10.1007/s00401-007-0231-8
144. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature (2007) 447(7143):482-6. doi:10.1038/nature05768
145. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol (1974) 111(1):58-64.
146. Campbell C, Risueno RM, Salati S, Guezguez B, Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr Opin Hematol (2008) 15(4):319-25. doi:10.1097/MOH.0b013e328303b9df
147. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2011) 8(2):97-106. doi:10.1038/nrclinonc.2010.196
148. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 24(3):385-98.
149. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature (2001) 411(6835):349-54. doi:10.1038/35077219
150. Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature (2013) 504(7478):143-7. doi:10.1038/nature12830
151. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 483(7390):474-8. doi:10.1038/nature10860
152. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer (2003) 3(2):89-101. doi:10.1038/nrc989
153. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 98(24):1777-85. doi:10.1093/jnci/djj495
154. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 68(14):5706-15. doi:10.1158/0008-5472.CAN-07-6878
155. Diessner J, Bruttel V, Stein R, Horn E, Häusler S, Dietl J, et al. Targeting of pre-existing and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 5:e1149. doi:10.1038/cddis.2014.115
156. Morrison BJ, Schmidt CW, Lakhani SR, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 10(4):210. doi:10.1186/bcr2111
157. Yi SY, Hao YB, Nan KJ, Fan TL. Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat Rev (2013) 39(3):290-6. doi:10.1016/j.ctrv.2012.10.004
158. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res (2011) 71(3):634-9. doi:10.1158/0008-5472.CAN-10-3220
159. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature (2012) 481(7379):85-9. doi:10.1038/nature10694
160. Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 68(5):1563-71. doi:10.1158/0008-5472.CAN-07-5324
161. Fridman WH, Teillaud JL, Sautes-Fridman C, Pages F, Galon J, Zucman-Rossi J, et al. The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol (2011) 2:66. doi:10.3389/fimmu.2011.00066
162. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13(9):1050-9. doi:10.1038/nm1622
163. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 8(1):59-73. doi:10.1038/nri2216
164. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466
165. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690
166. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369(2):122-33. doi:10.1056/NEJMoa1302369
167. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 18(8):1254-61. doi:10.1038/nm.2883
168. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 8(5):351-60. doi:10.1038/nrc2373
169. Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia (2014) 16(1):84-96. doi:10.1593/neo.131910
170. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother (2012) 61(3):353-62. doi:10.1007/s00262-011-1106-3